A study of the Celox Rapid dressing in severely bleeding patients

  • Research type

    Research Study

  • Full title

    Post-market Clinical Study to Evaluate the Clinical Performance and Safety of CELOX™ RAPID Haemostatic Z-Fold Gauze in Civilians with Life Threatening Bleeding Treated in a Pre-Hospital Setting

  • IRAS ID

    282441

  • Contact name

    Steve Bell

  • Contact email

    steve.bell@nwas.nhs.uk

  • Sponsor organisation

    Medtrade Products Ltd

  • Clinicaltrials.gov Identifier

    TRAU 49710, NIHR CRN reference

  • Duration of Study in the UK

    0 years, 10 months, 0 days

  • Research summary

    Celox Rapid, a haemostatic gauze, is an approved (CE marked) medical device available since 2012. This dressing is used in pre-hospital settings, mainly by ambulance or military personnel, in patients with life threatening emergency bleeding. The dressing is a temporary measure used to control the bleeding in the pre-hospital setting, with the aim of then transferring the injured patient to a medical facility, where the dressing is removed, underlying injuries assessed and continuing medical care provided.
    The purpose of this research study is to collect data on the performance and safety of the Celox Rapid dressing when used in a civilian setting by ambulance personnel in the UK.
    In order to capture data relating to the entire period of dressing use, this study will involve both the ambulance service that initially applied the Celox Rapid dressing(s) and the hospital where the patient is transferred to and where the dressing(s) will be removed.
    The Celox Rapid dressings will be used in this study in accordance with the approved instructions for use. Only patients with life threatening emergency bleeding that are treated with Celox Rapid will be eligible for inclusion. Data will be captured over the period of use of the dressing, which is expected to be less than 24 hours. Patients will not be required to undergo any additional tests, assessments or questionnaires as a result of participating in this study.
    The data generated by the study will help improve the understanding in the wider clinical community of the use and performance of this type of dressing, under normal conditions, in a civilian pre-hospital setting. The results may therefore be of benefit for the general population of future patients who present with life threatening bleeding in this setting.

  • REC name

    South Central - Oxford C Research Ethics Committee

  • REC reference

    22/SC/0046

  • Date of REC Opinion

    6 Jul 2022

  • REC opinion

    Further Information Favourable Opinion